Press coverage about Beigene (NASDAQ:BGNE) has been trending positive on Wednesday, Accern Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Beigene earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.2206126128417 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Beigene (BGNE) traded up $0.75 on Wednesday, reaching $156.23. 184,647 shares of the company’s stock were exchanged, compared to its average volume of 359,619. The company has a current ratio of 6.09, a quick ratio of 6.02 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $8,265.08, a PE ratio of -63.72 and a beta of 0.58. Beigene has a 52-week low of $34.36 and a 52-week high of $164.15.

Beigene (NASDAQ:BGNE) last released its earnings results on Wednesday, February 28th. The company reported ($2.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.40). The business had revenue of $18.17 million for the quarter, compared to analysts’ expectations of $23.00 million. sell-side analysts expect that Beigene will post -7.69 EPS for the current year.

BGNE has been the subject of a number of recent analyst reports. Maxim Group set a $120.00 price objective on shares of Beigene and gave the stock a “buy” rating in a research report on Tuesday, November 14th. Cowen reaffirmed a “buy” rating on shares of Beigene in a research report on Tuesday, November 14th. Finally, BidaskClub raised shares of Beigene from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $127.67.

In other Beigene news, Director Bros. Advisors Lp Baker purchased 1,980,198 shares of the company’s stock in a transaction that occurred on Thursday, January 18th. The shares were bought at an average cost of $101.00 per share, for a total transaction of $199,999,998.00. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, EVP Ji Li sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $146.88, for a total transaction of $1,468,800.00. Following the sale, the executive vice president now owns 10,000 shares in the company, valued at $1,468,800. The disclosure for this sale can be found here. Over the last quarter, insiders sold 164,475 shares of company stock worth $22,963,626. Corporate insiders own 19.90% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Marea Informative and is the sole property of of Marea Informative. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at

Beigene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with's FREE daily email newsletter.